Trial Profile
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Patients With Non Muscle Invasive Bladder Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Bladder cancer vaccine (Primary) ; Zastumotide (Primary) ; AS15
- Indications Bladder cancer
- Focus Adverse reactions
- 03 Feb 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 17 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 30 Dec 2011 New trial record